证券代码：300871 证券简称：回盛生物 公告编号：2026-001 武汉回盛生物科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于扭亏为盈情形。 三、业绩变动原因说明 1、报告期内，公司积极开拓海内外市场，营业收入实现国内、国外双 增长。报告期内归属于上市公司股东的净利润较上年同期大幅增长，主要原 因为公司营业收入增长促进净利润增长，同时公司技术创新升级、制剂与原 1 料药产能利用率提升及原料药价格上涨等因素驱动盈利能力提升。 2、报告期内，公司可转换公司债券提前赎回使得财务费用同比减少。 3、报告期内，预计公司非经常性损益对净利润的影响金额约为 2,250 万元。 四、其他相关说明 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 23,5 ...

Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Group 1 - The core stock price of Huisheng Biological (300871) closed at 20.73 yuan on December 31, 2025, reflecting an increase of 0.58% from the previous week's closing price of 20.61 yuan [1] - The highest intraday price for Huisheng Biological during the week was 21.01 yuan, while the lowest was 20.43 yuan [1] - The current total market capitalization of Huisheng Biological is 4.194 billion yuan, ranking 8th out of 11 in the animal health sector and 3819th out of 5181 in the A-share market [1] Group 2 - Huisheng Biological received the first phase of government subsidy amounting to 2.25 million yuan on December 26, 2025, which represents 11.16% of the latest audited net profit [1] - The total amount of the project subsidy is 10 million yuan, which will be disbursed in phases [1] - This subsidy is related to revenue and is associated with the company's regular business activities, and it has already been received [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Group 1 - The core point of the article is that Huisheng Biological (300871) has received a government subsidy of 2.25 million yuan, which is part of a total subsidy of 10 million yuan, aimed at supporting its operational activities [1] - As of December 30, 2025, Huisheng Biological's stock closed at 20.64 yuan, with a market capitalization of 4.176 billion yuan, reflecting a slight decline of 0.29% from the previous trading day [1] - The subsidy received represents 11.16% of the company's most recent audited net profit, indicating a significant impact on the company's financials [1] Group 2 - The company reported a trading volume of 64.4944 million yuan and a turnover rate of 1.54% on the day of the announcement [1] - The government subsidy is categorized as a revenue-related grant and is expected to have a positive impact on the company in the future, although it will not affect the profit for the fiscal year 2025 [1]

截至2025年12月29日收盘，回盛生物(300871)报收于20.7元，上涨0.44%，换手率2.48%，成交量5.01万 手，成交额1.03亿元。 当日关注点 武汉回盛生物科技股份有限公司于2025年12月26日收到首期政府补助资金225.00万元，项目补助总金额 为1,000.00万元，分阶段拨付。本次补助为与收益相关的政府补助，与日常经营活动相关，已实际到 账，占公司最近一期经审计净利润绝对值的11.16%。该笔补助不会对公司2025年度利润产生影响，未 来将根据项目进展对公司产生积极影响。具体会计处理以年度审计结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月29日主力资金净流入608.96万元，散户资金呈净流出态势。 来自公司公告汇总：回盛生物于12月26日收到首期政府补助225.00万元，占公司最近一期经审计 净利润绝对值的11.16%。 交易信息汇总资金流向 12月29日主力资金净流入608.96万元；游资资金净流入428.5万元；散户资金净流出1037.46万元。 公司公告汇总关于 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-104 武汉回盛生物科技股份有限公司 1 获得的政府补助属于与收益相关的政府补助。 2、补助的确认和计量 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、获得补助的基本情况 武汉回盛生物科技股份有限公司（以下简称"公司"）于近日收到地方政 府相关部门发放的首期政府补助资金 500.00 万元人民币，其中，归属于公司 的资金 225.00 万元。该项目的政府补助总金额为 1,000.00 万元，根据项目进 展，分期拨付以支持项目实施。 公司此次收到的政府补助情况如下： | 获得补助的主体 | 武汉回盛生物科技股份有限公司 | | --- | --- | | 收到补助的时间及金额 | 2025 年 12 月 26 日，225.00 万元 | | 补助形式和金额 | 现金 | | 占公司最近一期经审计净利润绝对值的比例 | 11.16% | | 是否与公司日常经营活动相关 | 是 | | 是否已经实际收到相关款项 | 是 | | 是否具有可持续性 | 否 | 二、补助的类型及 ...

Group 1 - The company, Huisheng Bio, announced on December 23 that its fourth board of directors' third meeting approved a proposal to use part of the idle raised funds for cash management [2]

Core Viewpoint - Wuhan Huisheng Biotechnology Co., Ltd. has approved the use of up to 40 million yuan of idle raised funds for cash management, ensuring that the use of these funds does not affect the normal operation of the company and its fundraising projects [1][2] Group 1 - The board meeting was held on December 23, 2025, with all five directors present, and the resolution was deemed legally valid [1] - The cash management will allow for a rolling use of funds within the approved limit for a period of 12 months, with the requirement to return the funds to the designated account after maturity [1] - The company emphasizes that this cash management will not impact the progress of fundraising projects or the company's main business operations [1] Group 2 - The sponsor, CITIC Securities Co., Ltd., has issued a no-objection opinion, confirming that the cash management aligns with regulatory requirements and enhances fund efficiency without harming the interests of the company and its shareholders [2] - The resolution received unanimous approval from the board, with 5 votes in favor and none against [2] - Market analysts suggest that utilizing idle raised funds for cash management can improve financial returns while controlling risks, which is expected to have a positive impact on the company's short-term performance [2]